Etoricoxib may be used together with low-dose aspirin in patients who require both pain relief and antiplatelet therapy, but the combination can increase gastrointestinal irritation. Your prescriber should weigh the benefits against the risks and may recommend a gastroprotective agent such as a proton-pump inhibitor.
For patients with mild to moderate renal impairment, the prescriber often starts at the lowest effective dose (60 mg) and monitors kidney function regularly. Severe renal disease generally contraindicates use.
Pain relief usually begins within 1-2 hours, with maximal effect by 4 hours. A single 120 mg dose is the typical regimen for acute gout, followed by assessment of response.
Etoricoxib can be taken with or without food. If you experience mild dyspepsia, taking it with a meal may improve tolerability.
Take the missed tablet as soon as you remember unless the next scheduled dose is due within a few hours. Do not double the dose; maintaining a regular once-daily schedule is preferable.
Yes, COX-2 inhibitors can raise blood pressure in some individuals. Regular monitoring is advised, especially for patients with pre-existing hypertension.
Etoricoxib is not recommended during pregnancy, particularly in the third trimester, due to potential fetal cardiovascular complications. If pain management is required during pregnancy, discuss alternative options with a healthcare professional.
When traveling, keep the medication in its original packaging, carry a copy of the prescription, and stay hydrated to reduce renal stress. Avoid excessive alcohol consumption, which can increase gastrointestinal irritation.
Etoricoxib selectively inhibits COX-2, offering comparable pain relief with a lower risk of stomach ulcers. However, it may carry a higher cardiovascular risk profile, which requires careful assessment in patients with heart disease.
Etoricoxib is a selective cyclo-oxygenase-2 (COX-2) inhibitor used to relieve pain and inflammation. It is marketed in the United Kingdom as a prescription-only pill and is available in strengths of 60 mg, 90 mg and 120 mg. The active ingredient is sold under several brand names, including Arcoxia, but the clinical information applies to the generic molecule itself.
The medication belongs to the broader pain-relief (non-steroidal anti-inflammatory drug, NSAID) category and is regulated by the UK Medicines and Healthcare products Regulatory Agency (MHRA).
Etoricoxib is authorised in the UK for the following indications, as per the MHRA label:
These uses are based on robust clinical trials demonstrating efficacy comparable to other NSAIDs while offering a lower gastrointestinal risk profile.
If any of these conditions apply, a healthcare professional should evaluate the suitability of etoricoxib on an individual basis.
Most of these events are transient and resolve without discontinuing therapy.
Any sudden chest pain, shortness of breath, severe abdominal pain, or abrupt swelling should prompt immediate medical attention.
Patients should disclose all prescription drugs, over-the-counter medicines, herbal supplements, and vitamins before starting etoricoxib.
Standard dosing (based on the approved strengths):
60 mg once daily for osteoarthritis.
90 mg once daily for rheumatoid arthritis or ankylosing spondylitis.
120 mg single dose for an acute gout flare or postoperative pain (may be followed by a lower maintenance dose if required).
Administration - swallow the pill whole with a glass of water; do not crush or chew.
Missed dose - take the missed tablet as soon as remembered unless the next scheduled dose is within a few hours. Do not double the dose.
Renal or hepatic impairment - the prescriber may start at the lowest dose (60 mg) and adjust based on clinical response and laboratory monitoring.
Overdose - symptoms may include nausea, vomiting, stomach pain, and dizziness. Seek emergency medical care; supportive measures are the mainstay of treatment, and activated charcoal may be considered if presentation is early.
Discontinuation - abrupt cessation is generally safe, but in patients on long-term therapy for chronic inflammatory disease, the prescriber may advise a gradual taper to avoid rebound pain.
Regular follow-up appointments allow the prescriber to balance pain control with safety considerations.
This article provides educational information about etoricoxib and is not a substitute for professional medical advice. Treatment decisions, including dosing, suitability, and the use of any medication for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes only and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
